In COPD patients, decreased levels of the proteoglycan decorin, along with increased expression of myostatin expression, could negatively impact normal muscle regeneration and growth, potentially by dysregulating the interplay between decorin/myostatin [11, 39]. Here, MSTN is linked to chronic obstructive pulmonary disease.